An important story in Cancerworld
Patient Support & Advocacy

An important story in Cancerworld

Cancerworld recently published an article by Ann Wagstaff titled Begging for imatinib: why do so many patients still lack access to this lifesaver?  It highlights the challenges people living with CML face in accessing imatinib, a life-extending medicine that has been generic for many years.  Here is our perspective on the story.

We have known for some time that most innovative drugs are not available in low-middle income countries (LMICs) and that patients needlessly suffer without treatment. The Max Foundation bridges this gap by developing access models in LMICs in collaboration with it partners to help patients in urgent need.

This article is important because it dispels common myths about access to innovative medicines after patient expiry in LMICs and underscores that availability of treatments does not by itself create access for patients. These myths prevent progress. By telling the story of one of the first orphan drugs in cancer and what took place when the originator lost patent exclusivity, the article highlights three critical lessons that we must consider when developing solutions:

  • As orphan drugs loose patent protection, we cannot expect that generics will come to markets in LMICs; availability of generics by themselves does not solve the problem. All stakeholders, including the innovative companies that develop medicines, bear responsibility and must continue to collaborate to improve access for patients.
  • High prices from the originator are not the only barrier to access for innovative medicines. Even when generics come to markets, especially in LMICs, they are still not affordable for most patients
  • Further, even in cases where generics are affordable or reimbursed, weaknesses in health care systems as well as budgetary pressures experienced by local governments often prevent access.

To achieve access for all, we must put the patient first and act as a global community instead of pushing responsibility on one another.  As a first step, we must agree on a definition of access meaning that it only exists when all patients are able to receive the right treatment and the right dose at the right time.

Only by putting the needs of patients’ first and working together as a community can we drive lasting changes that will deliver real solutions for patients in need.

See All Articles

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Building a Cancer Coalition in Guatemala

    Building a Cancer Coalition in Guatemala

    In Guatemala, there are 14,200 new cases of cancer a year and from this amount 9,100 people die of cancer or 64.7%. Most of these diagnoses could have been prevented or better treated if diagnosed early. In Guatemala only the persons who have access to the national social security plan have free services and treatment, but poor quality and lack of medications or in most occasions. People who do not have social security have to pay for health services and for medications. As per statistics taken from Globocan 2008, the most common cancers in Guatemala are prostate, cervix, stomach, breast and lung cancers.

  • Reflections Following the Loss of a Beloved Cancer Advocate

    Reflections Following the Loss of a Beloved Cancer Advocate

    The passing of our dear friend, advocate and colleague Ferdinand, has shaken the close-knit global chronic myeloid leukemia (CML) community. CML, a rare form of leukemia that used to be fatal, now is treated with innovative targeted therapies commonly referred to as TKIs. There has been unprecedented global access to these TKIs and this has fostered the development of one of the strongest global patient communities for a rare cancer. Ferdinand, from Nairobi, Kenya, was a loved member of this community.

  • Advocacy, a Technology Breakthrough, and a Celebration of Life

    Advocacy, a Technology Breakthrough, and a Celebration of Life

    On a dry sunny Saturday in Addis Ababa, more than 100 people sat in an auditorium at the Black Lion Hospital, intently listening to a panel of experts. Representatives from the Federal Ministry of Health, doctors, local and international NGOs, and concerned citizens, gathered together for the first time, to discuss the challenges of treating cancer in the country. People in the audience were not ordinary people; they were people who were affected by the dreaded C word, cancer. Most of them, parents whose children were undergoing treatment, some of them cancer survivors themselves.